Recent Updates
Recently added Catalysts

BON-C1393

Phase 1

Solid Tumors | Small molecule | Oncology |BeOne Medicines Ltd.|Trials Updated: Oct 29, 2026

BON-C1393 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment90

FDA Designations

No designations recorded

BON-C1393 clinical trials

BON-C1393 · 1 trial · 2 indications

Phase 1 1
NCT07904845A Study of BON-C1393 in Adults With Advanced Solid TumorsSolid Tumors
NOT YET_RECRUITING90 Analytics
PHASE1NOT YET_RECRUITING
A Study of BON-C1393 in Adults With Advanced Solid Tumors
Solid Tumors
NCT0790484590
Unlock trial analytics

Study Endpoints

Primary Endpoints

Phase 1a: Number of Participants with Dose-Limiting Toxicities (DLTs)
Approximately 1 month
Phase 1a: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)
Up to approximately 9 months
Phase 1b: Overall Response Rate (ORR) Assessed by the Investigator
Up to approximately 12 months

ORR is defined as the percentage of participants with a best overall response of partial response or better per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Secondary Endpoints

Phase 1a: Overall Response Rate (ORR) Assessed by the Investigator
Up to approximately 9 months
Phase 1a: Duration of Response (DOR) Assessed by the Investigator
Up to approximately 9 months
Phase 1b: Duration of Response (DOR) Assessed by the Investigator
Up to approximately 12 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase 1a Part A: Monotherapy Dose EscalationEXPERIMENTALSequential cohorts of increasing dose levels of BON-C1393 will be evaluated.
Phase 1a Part B: Monotherapy Dose ExplorationEXPERIMENTALParticipants with select advanced solid tumors will receive BON-C1393 at 2 - 3 selected dose levels that have been determined to be safe in Part A.
Phase 1b Part C: Monotherapy Dose ExpansionEXPERIMENTALParticipants with select advanced solid tumors will receive BON-C1393 as monotherapy at the recommended doses for expansion (RDFEs) identified in Phase 1a.
Phase 1b Part D: Dose Expansion Combination TherapyEXPERIMENTALParticipants with select advanced solid tumors will receive BON-C1393 in combination with bevacizumab and capecitabine.

Interventions

NameTypeDescription
BON-C1393DRUGAdministered intravenously
BevacizumabDRUGAdministered intravenously
CapecitabineDRUGAdministered orally
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic solid tumor intolerant, refractory to or progressing after standard systemic therapies. * Must be able to provide archival tumor tissue (formalin-fixed, paraffin-embedded tissue block (FFP...

Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Solid Tumors")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK3PHASE2Pembrolizumab, Gardasil 9
Incyte CorporationINCY1PHASE2Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115
Iovance Biotherapeutics IncIOVA2PHASE2Aldesleukin
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWOct 29, 2026NCT07904845NEW_TRIAL: changed
LOWOct 29, 2026NCT07904845NEW_TRIAL: changed

Explore more on BiopharmaWatch

BeOne Medicines Ltd. (ONC)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with BCompanies A to ZEvery biotech and pharma company we track